RICHARD SCHLOSS: Open Payments
NPI 1992856660 · HUNTINGTON, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,109 in 115 payments from 18 companies in 2025. Trend: 2023 $4,251 · 2024 $2,897 · 2025 $3,109
Food & beverage: $3,109
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 8 | $407 |
| Axsome Therapeutics, Inc. | 13 | $393 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $372 |
| Otsuka America Pharmaceutical, Inc. | 9 | $356 |
| E.R. Squibb & Sons, L.L.C. | 4 | $258 |
| ABBVIE INC. | 9 | $206 |
| Janssen Pharmaceuticals, Inc | 8 | $180 |
| Alkermes, Inc. | 9 | $169 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $169 |
| Lundbeck LLC | 13 | $152 |
Products named: REXULTI, INGREZZA, Auvelity, CAPLYTA, COBENFY, VRAYLAR, SPRAVATO, LYBALVI.
Industry payments across NY — which companies pay providers there.
